Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes

Bleachacz, 2008, Cholangiocarcinoma, Clin Liver Dis, 12, 131, 10.1016/j.cld.2007.11.003 Sempoux, 2011, Intrahepatic cholangiocarcinoma: new insights in pathology, Semin Liver Dis, 31, 104, 10.1055/s-0031-1272838 Khan, 2002, Changing international trends in mortality rates for liver, biliary and pancreatic tumours, J Hepatol, 37, 806, 10.1016/S0168-8278(02)00297-0 Singh, 2006, Advances in the diagnosis, evaluation and management of cholangiocarcinoma, Curr Opin Gastroenterol, 22, 294, 10.1097/01.mog.0000218967.60633.64 Valle, 2010, Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer, N Engl J Med, 362, 1273, 10.1056/NEJMoa0908721 Tan, 2008, Surgical management of intrahepatic cholangiocarcinoma–a population-based study, Ann Surg Oncol, 15, 600, 10.1245/s10434-007-9627-x Sia, 2013, Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies, Oncogene, 10.1038/onc.2012.617 Wehbe, 2006, Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression, Cancer Res, 66, 10517, 10.1158/0008-5472.CAN-06-2130 Isomoto, 2005, Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells, Hepatology, 42, 1329, 10.1002/hep.20966 Tannapfel, 2000, Frequency of p16 (INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver, Gut, 47, 721, 10.1136/gut.47.5.721 Momoi, 2001, Microsatellite instability and alternative genetic pathway in intrahepatic cholangiocarcinoma, J Hepatol, 35, 235, 10.1016/S0168-8278(01)00106-4 Terada, 1998, Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis, Hum Pathol, 29, 175, 10.1016/S0046-8177(98)90229-5 Terada, 1998, c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma, Histopathology, 33, 325, 10.1046/j.1365-2559.1998.00496.x Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857 Bengala, 2010, Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial, Br J Cancer, 102, 68, 10.1038/sj.bjc.6605458 Brunet, 2004, Metagenes and molecular pattern discovery using matrix factorization, Proc Natl Acad Sci U S A, 101, 4164, 10.1073/pnas.0308531101 Lee, 2004, Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling, Hepatology, 40, 667, 10.1002/hep.20375 Woo, 2010, Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma, Cancer Res, 70, 3034, 10.1158/0008-5472.CAN-09-2823 Boyault, 2007, Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets, Hepatology, 45, 42, 10.1002/hep.21467 Hoshida, 2009, Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma, Cancer Res, 69, 7385, 10.1158/0008-5472.CAN-09-1089 Bromberg, 1999, Stat3 as an oncogene, Cell, 98, 295, 10.1016/S0092-8674(00)81959-5 Gentile, 2011, Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis, Cancer Res, 71, 3132, 10.1158/0008-5472.CAN-10-2662 Montpetit, 2002, A detailed transcriptional map of the chromosome 12p12 tumour suppressor locus, Eur J Hum Genet, 10, 62, 10.1038/sj.ejhg.5200766 Lee, 2010, The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis, Proc Natl Acad Sci U S A, 107, 8248, 10.1073/pnas.0912203107 Andersen, 2012, Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors, Gastroenterology, 142, 1021, 10.1053/j.gastro.2011.12.005 Oishi, 2012, Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of mir-200c and EMT in intrahepatic cholangiocarcinoma, Hepatology, 56, 1792, 10.1002/hep.25890 Zhang, 1999, Transcriptional profiling of human microvascular endothelial cells in the proliferative and quiescent state using cDNA arrays, Angiogenesis, 3, 211, 10.1023/A:1009085422384 de Jong, 2011, Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment, J Clin Oncol, 29, 3140, 10.1200/JCO.2011.35.6519 Wang, 2009, IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway, J Exp Med, 206, 1457, 10.1084/jem.20090207 Isomoto, 2007, Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing, Gastroenterology, 132, 384, 10.1053/j.gastro.2006.10.037 Schreiber, 2011, Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science, 331, 1565, 10.1126/science.1203486 Roskams, 2006, Liver stem cells and their implication in hepatocellular and cholangiocarcinoma, Oncogene, 25, 3818, 10.1038/sj.onc.1209558 Chiang, 2008, Focal gains of VEGFA and molecular classification of hepatocellular carcinoma, Cancer Res, 68, 6779, 10.1158/0008-5472.CAN-08-0742 Blechacz, 2008, Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment, Hepatology, 48, 308, 10.1002/hep.22310 Rossi, 2010, A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer, Br J Cancer, 103, 1154, 10.1038/sj.bjc.6605872 Verstovsek, 2010, Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis, N Engl J Med, 363, 1117, 10.1056/NEJMoa1002028 Wang, 2006, Identification of intrahepatic cholangiocarcinoma related genes by comparison with normal liver tissues using expressed sequence tags, Biochem Biophys Res Commun, 345, 1022, 10.1016/j.bbrc.2006.04.175 Jinawath, 2006, Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma, Hepatology, 44, 1025, 10.1002/hep.21330 Miller, 2009, Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract, J Exp Clin Cancer Res, 28, 62, 10.1186/1756-9966-28-62 Yang, 2005, Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma, Mod Pathol, 18, 412, 10.1038/modpathol.3800287 Karamitopoulou, 2008, Clinical significance of cell cycle- and apoptosis-related markers in biliary tract cancer: a tissue microarray-based approach revealing a distinctive immunophenotype for intrahepatic and extrahepatic cholangiocarcinomas, Am J Clin Pathol, 130, 780, 10.1309/AJCP35FDCAVANWMM Hezel, 2010, Genetics of biliary tract cancers and emerging targeted therapies, J Clin Oncol, 28, 3531, 10.1200/JCO.2009.27.4787 Chin, 2011, Cancer genomics: from discovery science to personalized medicine, Nat Med, 17, 297, 10.1038/nm.2323 Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766 Soda, 2007, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature, 448, 561, 10.1038/nature05945 Flaherty, 2010, Inhibition of mutated, activated BRAF in metastatic melanoma, N Engl J Med, 363, 809, 10.1056/NEJMoa1002011 Chabner, 2011, Early accelerated approval for highly targeted cancer drugs, N Engl J Med, 364, 1087, 10.1056/NEJMp1100548 Stokes, 2011, Copy number and loss of heterozygosity detected by SNP array of formalin-fixed tissues using whole-genome amplification, PLoS One, 6, e24503, 10.1371/journal.pone.0024503 Quandt, 2011, B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response, Clin Cancer Res, 17, 3100, 10.1158/1078-0432.CCR-10-2268 Krambeck, 2006, B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival, Proc Natl Acad Sci U S A, 103, 10391, 10.1073/pnas.0600937103 Lu, 2010, Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver, Proc Natl Acad Sci U S A, 107, 1437, 10.1073/pnas.0911427107